Table 3: Recently Published Studies on Keratoplasty Indications
|
New Zealand |
China |
Scotland |
Canada |
Hungary |
| n = 2,253 |
n = 5,316 |
n = 921 |
n = 3,571 |
n = 402 |
| Cunningham et al. [8] |
Xie et al. [11] |
Ting et al. [6] |
Sheldon et al. [5] |
Mdis et al. [4] |
|
2000-2009 |
1996-2007 |
2001-2010 |
1995-2005 |
2006-2009 |
| Keratoconus |
938 |
41,6% |
674 |
12,7% |
264 |
28,7% |
592 |
16,6% |
60 |
14,9% |
| PBK/ABK |
315 |
14,0% |
353 |
6,6% |
88 |
9,6% |
790 |
22,1% |
116 |
28,9% |
| Fuchs Distrophy |
187 |
8,3% |
30 |
0,6% |
191 |
20,7% |
384 |
10,8% |
9 |
2,2% |
| Regraft |
391 |
17,4% |
246 |
4,6% |
177 |
19,2% |
755 |
21,1% |
74 |
18,4% |
| Keratitis |
180 |
8,0% |
2387 |
44,9% |
106 |
11,5% |
294 |
8,2% |
22 |
5,5% |
| Stromal opacities^ |
94 |
4,2% |
1195 |
22,5% |
21 |
2,3% |
573 |
16,0% |
74 |
18,4% |
| Others |
148 |
6,6% |
431 |
8% |
74 |
8,0% |
183 |
5,1% |
47 |
11,7% |
|
United Kingdom |
Iran |
Germany |
Australia |
Colombia (Present Study) |
| n = 22,779 |
n = 1,859 |
n = 1,200 |
n=22,898 |
n = 402 |
| Keenan et al. [7] |
Zare et al. [9] |
Wang et al. [10] |
Williams et al. [12] |
V. Galvis et al. |
|
1999-2009 |
2004-2009 |
2001-2010 |
1985-2011 |
2004-2011 |
| Keratoconus |
5469 |
24,0% |
714 |
38,4% |
306 |
25,5% |
6789 |
29,6% |
51 |
12,7% |
| PBK/ABK |
3597 |
15,8% |
218 |
11,7% |
175 |
14,6% |
4478 |
19,6% |
139 |
34,6% |
| Fuchs Distrophy |
4434 |
19,5% |
15 |
0,8% |
254 |
21,2% |
2790 |
12,2% |
30 |
7,5% |
| Regraft |
3318 |
14,6% |
197 |
10,6% |
84 |
7,0% |
4650 |
20,3% |
31 |
7,7% |
| Keratitis |
1885 |
8,3% |
188 |
10,1% |
156 |
13,0% |
1254 |
5,5% |
58 |
14,4% |
| Stromal opacities^ |
1437 |
6,3% |
297 |
16,0% |
198 |
16,5% |
1531 |
6,7% |
63 |
15,7% |
| Others |
2639 |
11,6% |
230 |
12,4% |
27 |
2,3% |
1406 |
6,1% |
30 |
7,5% |